Heron Therapeutics (HRTX) Competitors $1.52 -0.03 (-1.94%) As of 09:08 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends HRTX vs. SPRY, AVDL, BCYC, ZYME, NUVB, SEPN, COLL, PSTX, COGT, and GYREShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include ARS Pharmaceuticals (SPRY), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Zymeworks (ZYME), Nuvation Bio (NUVB), Septerna (SEPN), Collegium Pharmaceutical (COLL), Poseida Therapeutics (PSTX), Cogent Biosciences (COGT), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. ARS Pharmaceuticals Avadel Pharmaceuticals Bicycle Therapeutics Zymeworks Nuvation Bio Septerna Collegium Pharmaceutical Poseida Therapeutics Cogent Biosciences Gyre Therapeutics Heron Therapeutics (NASDAQ:HRTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Does the media prefer HRTX or SPRY? In the previous week, ARS Pharmaceuticals had 8 more articles in the media than Heron Therapeutics. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.88 beat ARS Pharmaceuticals' score of 0.79 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Heron Therapeutics Very Positive ARS Pharmaceuticals Positive Do analysts rate HRTX or SPRY? Heron Therapeutics currently has a consensus target price of $5.67, suggesting a potential upside of 265.59%. ARS Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 113.52%. Given Heron Therapeutics' higher probable upside, equities analysts clearly believe Heron Therapeutics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Does the MarketBeat Community prefer HRTX or SPRY? Heron Therapeutics received 645 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 82.61% of users gave ARS Pharmaceuticals an outperform vote while only 68.95% of users gave Heron Therapeutics an outperform vote. CompanyUnderperformOutperformHeron TherapeuticsOutperform Votes66468.95% Underperform Votes29931.05% ARS PharmaceuticalsOutperform Votes1982.61% Underperform Votes417.39% Which has preferable valuation and earnings, HRTX or SPRY? ARS Pharmaceuticals has lower revenue, but higher earnings than Heron Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$137.74M1.71-$110.56M-$0.18-8.61ARS Pharmaceuticals$2.57M425.37-$54.37M-$0.51-22.04 Do institutionals & insiders hold more shares of HRTX or SPRY? 80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 5.8% of Heron Therapeutics shares are owned by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, HRTX or SPRY? Heron Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Is HRTX or SPRY more profitable? ARS Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.31%. Heron Therapeutics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Heron Therapeutics-20.31% N/A -12.72% ARS Pharmaceuticals N/A -22.56%-21.82% SummaryHeron Therapeutics beats ARS Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$243.35M$6.65B$5.25B$8.88BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-8.6110.3386.4516.82Price / Sales1.71192.851,080.83127.60Price / CashN/A57.6943.2437.77Price / Book-6.744.975.104.93Net Income-$110.56M$153.69M$122.02M$227.55M7 Day Performance-6.63%-5.67%-3.03%-3.32%1 Month Performance-3.13%-2.01%19.58%0.38%1 Year Performance-27.91%-2.06%25.36%14.77% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.8922 of 5 stars$1.52-1.9%$5.67+272.8%-27.9%$231.18M$137.74M-8.44300Positive NewsSPRYARS Pharmaceuticals3.4175 of 5 stars$11.12-0.6%$24.00+115.8%+90.2%$1.08B$2.57M-21.8090Positive NewsAVDLAvadel Pharmaceuticals2.5962 of 5 stars$10.82-2.2%$24.43+125.8%-46.6%$1.04B$138.16M-13.70154Analyst ForecastAnalyst RevisionGap DownBCYCBicycle Therapeutics3.1151 of 5 stars$14.98+0.6%$35.25+135.3%-27.9%$1.03B$36.90M-4.55240Positive NewsZYMEZymeworks3.4878 of 5 stars$14.99-0.1%$19.17+27.9%+21.5%$1.03B$62.20M-9.99290Insider TradeGap DownNUVBNuvation Bio2.097 of 5 stars$2.87-0.7%$6.60+130.0%+76.6%$965.95M$2.16M-1.3260Gap UpSEPNSepterna2.0518 of 5 stars$21.74-8.2%$43.67+100.9%N/A$965.32M$981,000.000.00N/AGap DownCOLLCollegium Pharmaceutical3.9604 of 5 stars$29.18-1.1%$42.60+46.0%+1.2%$941.06M$599.25M12.58210Analyst UpgradeNews CoveragePSTXPoseida Therapeutics3.5497 of 5 stars$9.57+0.5%$9.50-0.7%N/A$935.70M$150.86M-15.19260COGTCogent Biosciences2.1821 of 5 stars$8.47+7.5%$14.83+75.1%+54.9%$935.61MN/A-3.4280Positive NewsGap DownGYREGyre Therapeutics0.2237 of 5 stars$9.98-7.5%N/A-55.6%$933.34M$105.03M0.0040 Related Companies and Tools Related Companies ARS Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Bicycle Therapeutics Competitors Zymeworks Competitors Nuvation Bio Competitors Septerna Competitors Collegium Pharmaceutical Competitors Poseida Therapeutics Competitors Cogent Biosciences Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HRTX) was last updated on 1/13/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
